Key clinical point: Compared with apixaban and dabigatran, rivaroxaban may cause greater variance in plasma drug concentration, which may make patients more susceptible to bleeding.
Major finding: Patients in the rivaroxaban group had significantly higher rates of GI bleeding, compared with those in the group receiving either apixaban or dabigatran (1.2 vs. 0.6 events per 100 patient-years, respectively).
Study details: A population-based study that compared 4-year GI bleeding rates of 2,635 patients who received rivaroxaban with 2,365 patients who received either apixaban or dabigatran.
Disclosures: The researchers reported having no financial disclosures.
REPORTING FROM DDW 2019